China’s Aida Pharmaceutials Inc said it plans to diversify revenue streams away from an over-reliance on its Etimicin chain of antibiotics.   “Aida is positioning the Company to become less reliant on this single drug by further diversifying our drug portfolio. We are succeeding in this endeavor and anticipate bringing seven new drugs to market, with two drugs in 2008 and 2010, respectively, and the others in annual intervals thereafter,” said the company in a press release.   Aida reported profits of $1.47 million on revenues of $24.53 million at year end 2005. It reported revenues of $5.33 million in the first quarter of 2006. For the same period, cash and cash equivalents amounted to $2.27 million. "These financial results were primarily driven by the success of Etimicin Sulfate, Not only is Etimicin a steady grower and cash earner for us, but our competitive advantage provides some control of the manufacturing and distrubution costs of thsi drug, " the company added.